


Supplementary Information

Supplementary Figure 1. Age of patients hospitalised with COVID-19 and of patients hospitalised with influenza

Individuals hospitalised with COVID-19 between December 2019 and April 2020 compared with those hospitalised with influenza between September 2009 to April 2010. Proportion of cohorts by 5-year age groups, with counts of less than 10 omitted. CUIMC: Columbia University Irving Medical Center; HIRA: Health Insurance Review & Assessment; HM: HM Hospitales; PHD: Premier Healthcare Database; SIDIAP: The Information System for Research in Primary Care; UC HDC: University of Colorado Health Data Compass; VA OMOP: Department of Veterans Affairs.



Supplementary Figure 2. Characteristics of COVID-19 patients compared to 2009-2010 Influenza patients

The plot compares demographics (age and sex), conditions (recorded over the year prior and up to day of hospitalisation), and medications (1) from a year prior up to, and including, day of hospitalisation, 2) from 30 days prior up to, and including, day of hospitalisation, and 3) on day of hospitalisation). Each dot represents one of these covariates with the colour indicating the absolute value of the standardised mean difference (SMD), with a SMD above 0.1 taken to indicate a difference in the prevalence of a particular covariate. The proportion male, with heart disease, with chronic obstructive pulmonary disease (COPD) and taking immunosuppressants (over the 30 days prior up to, and including, day of hospitalisation) are shown for illustration. CUIMC: Columbia University Irving Medical Center; SIDIAP: The Information System for Research in Primary Care; VA OMOP: Department of Veterans Affairs.

Supplementary Table 1. Characteristics of individuals hospitalised with COVID-19 compared with those hospitalised with influenza in 2015-2019

	CUIM C COVID -19	CUIMC Influenz a 2014- 19	CUIM C SMD	PHD COVID -19	PHD Influenz a 2014- 19	PHD SM D	SIDIAP COVID -19	SIDIAP Influenz a 2014- 19	SIDIA P SMD	UC HDC COVID -19	UC HDC Influenz a 2014- 19	UC HDC SM D	VA OMOP COVID -19	VA OMOP Influenz a 2014- 19	VA OMO P SMD
sex: male	52.0%	43.1%	0.09	52.4%	44.1%	0.08	54.4%	52.9%	0.01	53.7%	44.9%	0.09	94.3%	94.1%	0.00
sex: female	47.9%	56.9%	-0.09	47.6%	55.9%	- 0.08	45.6%	47.1%	-0.02	46.3%	54.9%	- 0.09	5.7%	5.9%	-0.01
age group: 15-19	<0.6%	1.2%		0.4%	0.4%	0.00	0.1%	0.6%	-0.06		0.4%				
age group: 20-24	1.4%	3.2%	-0.08	1.7%	1.5%	0.01	0.7%	1.3%	-0.04	1.7%	2.6%	- 0.04	<1.7%		
age group: 25-29	2.3%	4.0%	-0.07	2.7%	2.2%	0.02	1.2%	2.0%	-0.04	2.7%	3.4%	- 0.03	<1.7%	0.4%	
age group: 30-34	3.2%	3.8%	-0.02	3.5%	2.4%	0.05	2.0%	2.7%	-0.03	4.7%	3.6%	0.04	<1.7%	0.8%	
age group: 35-39	3.5%	3.1%	0.02	3.7%	2.6%	0.04	3.0%	3.9%	-0.03	5.2%	3.9%	0.04	2.4%	1.0%	0.08
age group: 40-44	3.0%	3.0%	0.00	4.9%	2.9%	0.07	5.1%	4.9%	0.01	6.5%	3.9%	0.08	2.6%	1.1%	0.08
age group: 45-49	4.3%	3.8%	0.02	6.2%	4.3%	0.06	6.7%	5.3%	0.04	7.0%	4.9%	0.06	3.8%	2.1%	0.07
age group: 50-54	6.4%	5.8%	0.02	7.1%	5.9%	0.03	8.1%	6.0%	0.06	7.4%	6.2%	0.03	6.4%	3.7%	0.09
age group: 55-59	8.0%	6.6%	0.04	10.4%	9.3%	0.02	9.6%	7.0%	0.06	10.4%	8.5%	0.04	9.2%	7.5%	0.04

age group: 60-64	9.3%	8.6%	0.02	10.7%	11.2%	- 0.01	9.5%	7.4%	0.05	10.9%	10.6%	0.01	13.9%	12.4%	0.03
age group: 65-69	10.5%	9.8%	0.02	9.6%	10.9%	- 0.03	9.0%	9.5%	-0.01	10.5%	11.0%	- 0.01	12.8%	19.1%	-0.11
age group: 70-74	10.9%	9.3%	0.04	10.9%	11.9%	- 0.02	10.4%	10.9%	-0.01	9.8%	10.0%	0.00	19.8%	19.7%	0.00
age group: 75-79	10.9%	10.3%	0.01	9.1%	11.2%	- 0.05	10.9%	10.7%	0.00	8.2%	8.9%	- 0.02	11.1%	9.6%	0.03
age group: 80-84	9.9%	9.7%	0.00	7.5%	9.5%	- 0.05	9.3%	12.6%	-0.07	6.0%	8.6%	- 0.07	5.0%	8.2%	-0.09
age group: 85-89	7.9%	8.1%	0.00	8.8%	13.8%	- 0.11	8.6%	8.7%	0.00	5.6%	6.6%	- 0.03	5.9%	7.3%	-0.04
age group: 90-94	6.1%	6.5%	-0.01	2.6%	0.1%	0.15	4.5%	5.2%	-0.02	2.3%	5.1%	- 0.10	3.1%	5.3%	-0.08
age group: 95-99	1.8%	2.4%	-0.03				1.2%	1.2%	0.00	<1.3%	1.3%		<1.7%	1.6%	
age group: 00-04	<0.6%	0.6%					0.1%	<0.3%		<1.3%	<0.3%			0.1%	
age group: 05-10															
Charlson comorbidity index	4.0	5.7	-0.29	3.1	3.1	0.00	1.5	3.5	-0.59	3.5	4.3	- 0.16	5.4	5.9	-0.09
Anemia	13.1%	25.5%	-0.20	30.2%	26.8%	0.05	14.6%			29.9%	37.6%	- 0.09	30.0%	27.3%	0.04
Anxiety disorder	5.5%	9.7%	-0.11	18.0%	18.6%	- 0.01	23.7%	20.2%	0.05	18.2%	26.9%	- 0.13	30.3%	29.0%	0.02
Asthma	7.2%	21.2%	-0.26	14.6%	14.0%	0.01	6.9%	12.2%	-0.12	13.8%	24.3%	- 0.17	9.9%	8.3%	0.04
Atrial fibrillation	8.4%	20.0%	-0.22	18.1%	22.6%	- 0.07	8.2%	16.4%	-0.17	12.0%	18.1%	- 0.11	15.8%	20.8%	-0.08
Chronic liver disease	2.6%	5.2%	-0.09	3.0%	2.8%	0.01	1.9%	7.0%	-0.17	2.3%	5.3%	- 0.11	6.8%	7.5%	-0.02
COPD	6.1%	18.3%	-0.25	24.5%	36.6%	- 0.15	7.6%	23.2%	-0.28	12.6%	31.1%	- 0.28	28.6%	43.0%	-0.17

Dementia	8.5%	9.4%	-0.02	9.2%	9.9%	- 0.02	5.6%	5.3%	0.01	7.4%	8.1%	- 0.02	7.8%	10.2%	-0.06
Diabetes mellitus	24.2%	32.2%	-0.11	35.8%	34.0%	0.02	21.6%	29.3%	-0.11	35.2%	31.8%	0.04	43.3%	43.1%	0.00
Gastroesophageal reflux disease	9.6%	16.4%	-0.13	24.8%	25.2%	- 0.01	9.5%	6.2%	0.08	23.4%	35.0%	- 0.15	26.9%	29.1%	-0.03
Heart disease	28.3%	53.0%	-0.27	48.6%	54.2%	- 0.06	27.1%	49.1%	-0.25	39.0%	55.8%	- 0.17	48.2%	58.2%	-0.10
Heart failure	10.7%	25.8%	-0.25	24.8%	28.1%	- 0.05	5.9%	20.0%	-0.28	12.9%	23.1%	- 0.17	22.2%	25.7%	-0.05
Hyperlipidemia	24.7%	33.1%	-0.11	46.0%	45.1%	0.01	23.7%	39.8%	-0.20	38.0%	43.0%	- 0.06	55.8%	58.5%	-0.03
Hypertensive disorder	36.6%	50.6%	-0.15	47.1%	41.1%	0.06	45.6%	55.8%	-0.10	57.3%	62.5%	- 0.05	69.7%	71.8%	-0.02
Insomnia	3.1%	5.6%	-0.08	4.4%	3.3%	0.04	14.6%	12.6%	0.04	7.4%	10.4%	- 0.07	10.9%	9.9%	0.02
lschemic heart disease	8.0%	15.2%	-0.15	16.0%	16.8%	- 0.01	7.3%	17.1%	-0.20	13.5%	17.5%	- 0.07	15.6%	21.3%	-0.09
Low back pain	6.8%	8.9%	-0.05	5.0%	2.7%	0.08	21.9%	25.7%	-0.06	11.1%	14.0%	- 0.06	30.0%	26.4%	0.05
Malignant neoplastic disease	7.7%	17.5%	-0.20	9.4%	8.5%	0.02	15.8%	23.5%	-0.12	10.8%	19.3%	- 0.15	18.4%	21.4%	-0.05
Osteoarthritis of knee	4.6%	4.4%	0.01	2.0%	1.3%	0.04	14.8%	11.9%	0.06	5.1%	4.7%	0.01	11.4%	6.6%	0.11
Osteoarthritis of hip	3.0%	3.2%	-0.01	1.1%	0.5%	0.05	5.1%	3.8%	0.04	2.6%	2.1%	0.02	2.8%	1.8%	0.05
Peripheral vascular disease	4.7%	5.9%	-0.04	7.5%	6.2%	0.04	3.9%	24.8%	-0.39	7.4%	6.9%	0.01	10.6%	12.7%	-0.04
Renal impairment	21.1%	34.9%	-0.18	37.5%	36.9%	0.01	13.1%	26.9%	-0.22	37.2%	39.5%	- 0.03	32.9%	32.2%	0.01

Venous thrombosis	2.3%	7.7%	-0.17	2.0%	1.8%	0.01	1.5%	2.6%	-0.05	6.6%	7.7%	- 0.03	4.0%	4.0%	0.00
Viral hepatitis	2.3%	3.9%	-0.06	2.5%	2.4%	0.00	1.7%	4.8%	-0.12	2.6%	3.9%	- 0.05	5.9%	6.3%	-0.01
Antineoplastic and immunomodulating agents (year up to, and including, index date)	9.6%	21.3%	-0.21	3.8%	2.6%	0.05	3.4%	8.9%	-0.16	12.9%	23.0%	- 0.17	13.2%	13.5%	-0.01
Antineoplastic and immunomodulating agents (30 days up to, and including, index date)	6.1%	17.0%	-0.23	2.6%	2.4%	0.01	2.7%	7.7%	-0.15	9.6%	18.3%	- 0.16	7.1%	8.5%	-0.04
Antineoplastic and immunomodulating agents (on index date)	4.9%	15.0%	-0.23	2.1%	2.0%	0.00	2.5%	7.6%	-0.16	8.2%	16.7%	- 0.17	4.9%	6.7%	-0.05
Agents acting on the renin- angiotensin system (year up to, and including, index date)	27.3%	36.3%	-0.11	15.3%	12.7%	0.05	30.2%	38.2%	-0.10	39.8%	40.9%	- 0.01	49.6%	50.8%	-0.01
Agents acting on the renin- angiotensin system (30 days up to, and including, index date)	18.0%	25.1%	-0.11	8.8%	11.8%	- 0.07	26.6%	33.7%	-0.09	33.0%	35.8%	- 0.03	38.5%	41.0%	-0.03
Agents acting on the renin- angiotensin system (on index date)	15.9%	23.8%	-0.13	7.4%	11.0%	- 0.08	25.7%	32.5%	-0.09	31.5%	34.9%	- 0.04	33.1%	38.8%	-0.07

Antiepileptics (year up to, and including, index date)	19.0%	24.9%	-0.09	16.7%	15.9%	0.01	10.6%	15.3%	-0.09	27.2%	33.0%	- 0.07	33.4%	37.4%	-0.05
Antiepileptics (30 days up to, and including, index date)	9.9%	17.0%	-0.14	12.2%	15.3%	- 0.06	8.1%	12.1%	-0.09	21.6%	27.1%	- 0.08	22.7%	30.0%	-0.10
Antiepileptics (on index date)	9.1%	15.7%	-0.13	11.3%	14.8%	- 0.07	7.7%	11.7%	-0.09	20.2%	26.5%	- 0.09	16.6%	28.4%	-0.18
Antiinflammatory and antirheumatic products (year up to index date)	23.6%	34.2%	-0.14	17.5%	14.9%	0.05	30.9%	34.8%	-0.05	52.9%	74.8%	- 0.19	46.1%	36.0%	0.11
Antiinflammatory and antirheumatic products (30 days up to, and including, index date)	10.5%	20.0%	-0.17	10.2%	14.2%	- 0.08	9.9%	15.1%	-0.10	38.6%	62.3%	- 0.24	16.8%	17.3%	-0.01
Antiinflammatory and antirheumatic products (on index date)	7.8%	17.1%	-0.19	7.9%	12.3%	- 0.10	6.3%	11.1%	-0.12	35.1%	59.3%	- 0.25	9.9%	13.2%	-0.07
Antithrombotic agents (year up to, and including, index date)	44.9%	75.0%	-0.27	50.1%	49.0%	0.01	25.7%	39.1%	-0.17	72.0%	75.9%	- 0.03	55.8%	72.0%	-0.14
Antithrombotic agents (30 days up to, and including, index date)	29.9%	64.8%	-0.36	40.4%	47.7%	- 0.08	21.9%	35.0%	-0.17	67.5%	68.4%	- 0.01	42.1%	61.4%	-0.19

Antithrombotic agents (on index date)	28.3%	63.5%	-0.37	38.4%	46.7%	- 0.09	21.3%	34.3%	-0.17	66.8%	67.3%	0.00	35.5%	59.0%	-0.24
Beta blocking agents (year up to, and including, index date)	26.9%	39.5%	-0.15	26.7%	25.7%	0.01	13.8%	22.9%	-0.15	32.8%	42.7%	- 0.11	44.4%	53.3%	-0.09
Beta blocking agents (30 days up to, and including, index date)	16.8%	31.0%	-0.21	19.3%	24.6%	- 0.08	12.4%	20.3%	-0.14	24.7%	35.6%	- 0.14	36.0%	46.0%	-0.11
Beta blocking agents (on index date)	15.2%	29.9%	-0.22	17.8%	23.8%	- 0.09	11.9%	19.7%	-0.14	23.8%	34.4%	- 0.14	31.0%	44.5%	-0.16
Calcium channel blockers (year up to, and including, index date)	23.5%	32.5%	-0.12	17.4%	15.0%	0.04	12.4%	18.9%	-0.12	24.3%	27.8%	- 0.05	35.0%	34.4%	0.01
Calcium channel blockers (30 days up to, and including, index date)	15.0%	22.5%	-0.12	11.1%	14.2%	- 0.06	10.5%	15.5%	-0.10	20.5%	22.2%	- 0.03	27.0%	26.8%	0.00
Calcium channel blockers (on index date)	13.4%	21.1%	-0.13	9.7%	13.4%	- 0.08	10.1%	15.0%	-0.10	19.9%	21.3%	- 0.02	24.3%	25.5%	-0.02
Diuretics (year up to, and including, index date)	27.6%	42.4%	-0.18	22.7%	19.4%	0.05	24.6%	38.9%	-0.18	33.3%	42.8%	- 0.11	42.6%	47.1%	-0.05
Diuretics (30 days up to, and including, index date)	19.2%	32.2%	-0.18	15.6%	18.2%	- 0.04	21.5%	34.4%	-0.17	27.4%	35.6%	- 0.10	33.1%	37.1%	-0.05

Diuretics (on index date)	17.7%	30.2%	-0.18	14.1%	17.2%	- 0.06	20.7%	33.6%	-0.17	26.4%	34.6%	- 0.10	28.4%	34.7%	-0.08
Drugs for acid related disorders (year up to, and including, index date)	35.4%	60.0%	-0.25	34.5%	31.4%	0.04	30.4%	60.3%	-0.31	53.6%	67.7%	- 0.13	52.0%	60.7%	-0.08
Drugs for acid related disorders (30 days up to, and including, index date)	20.6%	45.2%	-0.30	23.7%	30.0%	- 0.09	22.7%	51.6%	-0.34	44.5%	58.7%	- 0.14	36.2%	47.5%	-0.12
Drugs for acid related disorders (on index date)	17.9%	42.5%	-0.32	21.8%	28.5%	- 0.09	21.5%	50.5%	-0.34	42.4%	56.8%	- 0.14	28.9%	44.8%	-0.19
Immunosuppressan ts (year up to, and including, index date)	5.6%	13.4%	-0.18	2.2%	1.4%	0.04	2.3%	7.0%	-0.15	7.5%	11.5%	- 0.09	5.7%	5.4%	0.01
Immunosuppressan ts (30 days up to, and including, index date)	3.9%	11.5%	-0.19	1.6%	1.3%	0.02	1.9%	6.3%	-0.15	6.1%	9.6%	- 0.09	3.5%	4.1%	-0.02
lmmunosuppressan ts (on index date)	3.7%	10.7%	-0.18	1.5%	1.3%	0.01	1.7%	6.2%	-0.16	5.9%	9.3%	- 0.09	2.6%	3.7%	-0.04
Insulins and analogues (year up to, and including, index date)	17.8%	31.7%	-0.20	19.2%	18.0%	0.02	5.5%	11.0%	-0.14	31.9%	28.8%	0.04	22.9%	30.0%	-0.10
Insulins and analogues (30 days up to, and including, index date)	10.9%	22.3%	-0.20	13.9%	17.3%	- 0.06	4.9%	10.5%	-0.14	26.9%	24.7%	0.03	18.4%	24.0%	-0.09

Insulins and analogues (on index date)	9.9%	21.2%	-0.20	13.1%	16.7%	- 0.07	4.7%	10.3%	-0.14	25.4%	23.9%	0.02	14.6%	22.6%	-0.13
Lipid modifying agents (year up to, and including, index date)	33.8%	43.6%	-0.11	27.6%	27.2%	0.01	26.8%	36.3%	-0.12	41.7%	43.6%	- 0.02	61.9%	63.5%	-0.01
Lipid modifying agents (30 days up to, and including, index date)	20.8%	35.2%	-0.19	21.0%	26.4%	- 0.08	23.6%	32.8%	-0.12	36.4%	39.1%	- 0.03	50.8%	54.5%	-0.04
Lipid modifying agents (on index date)	18.7%	34.0%	-0.21	19.9%	25.8%	- 0.09	23.0%	32.4%	-0.13	35.6%	38.2%	- 0.03	43.8%	52.7%	-0.09

CUIMC: Columbia University Irving Medical Center; HIRA: Health Insurance Review & Assessment; HM: HM Hospitales; PHD: Premier Healthcare Database; SIDIAP: The Information System for Research in Primary Care; UC HDC: University of Colorado Health Data Compass; VA OMOP: Department of Veterans Affairs. COPD: Chronic obstructive pulmonary disease; GERD: Gastroesophageal reflux disease. Exact proportions have not been reported where counts were less than 10.

Supplementary Table 2. Characteristics of individuals hospitalised with COVID-19 compared with those hospitalised with influenza in 2009-2010

	CUIMC COVID-19	CUIMC Influenza 2009-10	CUIMC SMD	SIDIAP COVID-19	SIDIAP Influenza 2009-10	SIDIAP SMD	VA OMOP COVID-19	VA OMOP Influenza 2009- 10	VA OMOP SMD
sex: male	52.0%	39.4%	0.13	54.4%	48.8%	0.06	94.3%	91.4%	0.02
sex: female	47.9%	60.6%	-0.12	45.6%	51.2%	-0.06	5.7%	8.6%	-0.08
age group: 15-19	<0.6%	<5.9%		0.1%	<1.7%				
age group: 20-24	1.4%	7.1%	-0.20	0.7%	4.5%	-0.17	<1.7%	<0.6%	
age group: 25-29	2.3%	8.8%	-0.19	1.2%	9.2%	-0.25	<1.7%	2.7%	
age group: 30-34	3.2%	<5.9%		2.0%	8.4%	-0.20	<1.7%	2.1%	
age group: 35-39	3.5%	<5.9%		3.0%	10.8%	-0.21	2.4%	2.4%	0.00
age group: 40-44	3.0%	<5.9%		5.1%	10.8%	-0.14	2.6%	4.1%	-0.06
age group: 45-49	4.3%	8.2%	-0.11	6.7%	10.4%	-0.09	3.8%	7.8%	-0.12
age group: 50-54	6.4%	9.4%	-0.08	8.1%	8.2%	0.00	6.4%	14.0%	-0.17
age group: 55-59	8.0%	11.2%	-0.07	9.6%	9.1%	0.01	9.2%	17.7%	-0.16
age group: 60-64	9.3%	10.6%	-0.03	9.5%	6.0%	0.09	13.9%	21.0%	-0.12
age group: 65-69	10.5%	6.5%	0.10	9.0%	8.6%	0.01	12.8%	9.6%	0.07
age group: 70-74	10.9%	9.4%	0.03	10.4%	4.8%	0.14	19.8%	5.3%	0.29
age group: 75-79	10.9%	6.5%	0.11	10.9%	5.0%	0.15	11.1%	5.0%	0.15
age group: 80-84	9.9%	<5.9%		9.3%	2.2%	0.21	5.0%	3.4%	0.06
age group: 85-89	7.9%	<5.9%		8.6%	<1.7%		5.9%	3.4%	0.08
age group: 90-94	6.1%	<5.9%		4.5%	<1.7%		3.1%	0.7%	0.12
age group: 95-99	1.8%	<5.9%		1.2%			<1.7%	<0.6%	
age group: 00-04	<0.6%	<5.9%		0.1%					
age group: 05-10									
charlson index	4.0	4.8	-0.13	1.5	1.6	-0.03	5.4	4.2	0.24

Anemia	13.1%	24.1%	-0.18	14.6%			30.0%	23.0%	0.10
Anxiety disorder	5.5%	10.6%	-0.13	23.7%	14.9%	0.14	30.3%	29.4%	0.01
Asthma	7.2%	27.6%	-0.35	6.9%	16.4%	-0.20	9.9%	12.6%	-0.06
Atrial fibrillation	8.4%	11.2%	-0.06	8.2%	5.8%	0.06	15.8%	9.9%	0.12
Chronic liver disease	2.6%	8.2%	-0.17	1.9%	6.0%	-0.15	6.8%	7.6%	-0.02
COPD	6.1%	14.7%	-0.19	7.6%	14.7%	-0.15	28.6%	31.0%	-0.03
Dementia	8.5%	<5.9%		5.6%	<1.7%		7.8%	2.2%	0.18
Diabetes mellitus	24.2%	28.2%	-0.06	21.6%	13.5%	0.14	43.3%	36.1%	0.08
Gastroesophageal reflux disease	9.6%	13.5%	-0.08	9.5%	<1.7%		26.9%	27.2%	0.00
Heart disease	28.3%	47.6%	-0.22	27.1%	21.6%	0.08	48.2%	43.9%	0.04
Heart failure	10.7%	22.9%	-0.21	5.9%	6.5%	-0.02	22.2%	15.7%	0.11
Hyperlipidemia	24.7%	26.5%	-0.03	23.7%	22.4%	0.02	55.8%	52.9%	0.03
Hypertensive disorder	36.6%	54.1%	-0.18	45.6%	30.1%	0.18	69.7%	65.7%	0.03
Insomnia	3.1%	<5.9%		14.6%	2.9%	0.28	10.9%	6.6%	0.10
Ischemic heart disease	8.0%	14.7%	-0.14	7.3%	6.7%	0.02	15.6%	20.3%	-0.08
Low back pain	6.8%	11.8%	-0.12	21.9%	16.8%	0.08	30.0%	22.6%	0.10
Malignant neoplastic disease	7.7%	11.8%	-0.09	15.8%	9.6%	0.12	18.4%	19.2%	-0.01
Osteoarthritis of knee	4.6%	<5.9%		14.8%	3.8%	0.26	11.4%	1.1%	0.29
Osteoarthritis of hip	3.0%			5.1%	<1.7%		2.8%		
Peripheral vascular disease	4.7%	<5.9%		3.9%	10.8%	-0.18	10.6%	7.4%	0.08
Renal impairment	21.1%	26.5%	-0.08	13.1%	7.9%	0.11	32.9%	19.2%	0.19
Venous thrombosis	2.3%	<5.9%		1.5%	<1.7%		4.0%	2.5%	0.06
Viral hepatitis	2.3%	6.5%	-0.14	1.7%	3.6%	-0.08	5.9%	9.5%	-0.09
Antineoplastic and immunomodulating agents (year up to index date)	9.6%	12.9%	-0.07	3.4%	3.6%	-0.01	13.2%	14.0%	-0.02
Antineoplastic and immunomodulating agents (30 days up to index date)	6.1%	11.2%	-0.12	2.7%	2.7%	0.00	7.1%	8.8%	-0.04

Antineoplastic and immunomodulating agents (on index date)	4.9%	10.0%	-0.13	2.5%	2.6%	0.00	4.9%	7.2%	-0.07
Agents acting on the renin-angiotensin system (year up to index date)	27.3%	34.7%	-0.09	30.2%	19.5%	0.15	49.6%	50.4%	-0.01
Agents acting on the renin-angiotensin system (30 days up to index date)	18.0%	27.1%	-0.14	26.6%	17.8%	0.13	38.5%	41.3%	-0.03
Agents acting on the renin-angiotensin system (on index date)	15.9%	25.9%	-0.15	25.7%	17.0%	0.13	33.1%	40.1%	-0.08
Antiepileptics (year up to index date)	19.0%	11.2%	0.14	10.6%	9.1%	0.03	33.4%	32.0%	0.02
Antiepileptics (30 days up to index date)	9.9%	9.4%	0.01	8.1%	7.7%	0.01	22.7%	25.3%	-0.04
Antiepileptics (on index date)	9.1%	9.4%	-0.01	7.7%	6.7%	0.03	16.6%	23.8%	-0.11
Antiinflammatory and antirheumatic products (year up to index date)	23.6%	21.8%	0.03	30.9%	51.4%	-0.23	46.1%	41.6%	0.05
Antiinflammatory and antirheumatic products (30 days up to index date)	10.5%	13.5%	-0.06	9.9%	26.7%	-0.28	16.8%	20.2%	-0.06
Antiinflammatory and antirheumatic products (on index date)	7.8%	13.5%	-0.12	6.3%	21.1%	-0.28	9.9%	17.0%	-0.14
Antithrombotic agents (year up to index date)	44.9%	55.3%	-0.10	25.7%	16.3%	0.14	55.8%	63.5%	-0.07
Antithrombotic agents (30 days up to index date)	29.9%	43.5%	-0.16	21.9%	14.7%	0.12	42.1%	51.8%	-0.10
Antithrombotic agents (on index date)	28.3%	41.8%	-0.16	21.3%	13.9%	0.12	35.5%	49.7%	-0.15
Beta blocking agents (year up to index date)	26.9%	28.2%	-0.02	13.8%	10.3%	0.07	44.4%	47.6%	-0.03
Beta blocking agents (30 days up to index date)	16.8%	23.5%	-0.11	12.4%	8.7%	0.08	36.0%	39.6%	-0.04
Beta blocking agents (on index date)	15.2%	22.9%	-0.12	11.9%	8.7%	0.07	31.0%	38.7%	-0.09
Calcium channel blockers (year up to index date)	23.5%	21.2%	0.03	12.4%	7.9%	0.10	35.0%	28.2%	0.09
Calcium channel blockers (30 days up to index date)	15.0%	17.1%	-0.04	10.5%	6.7%	0.09	27.0%	22.2%	0.07

Calcium channel blockers (on index date)	13.4%	15.3%	-0.04	10.1%	6.2%	0.10	24.3%	21.3%	0.04
Diuretics (year up to index date)	27.6%	34.1%	-0.08	24.6%	18.2%	0.10	42.6%	46.7%	-0.04
Diuretics (30 days up to index date)	19.2%	28.8%	-0.14	21.5%	15.8%	0.09	33.1%	36.5%	-0.04
Diuretics (on index date)	17.7%	25.9%	-0.12	20.7%	14.7%	0.10	28.4%	33.6%	-0.07
Drugs for acid related disorders (year up to index date)	35.4%	57.6%	-0.23	30.4%	40.2%	-0.12	52.0%	65.2%	-0.12
Drugs for acid related disorders (30 days up to index date)	20.6%	47.1%	-0.32	22.7%	29.3%	-0.09	36.2%	53.0%	-0.18
Drugs for acid related disorders (on index date)	17.9%	43.5%	-0.33	21.5%	26.0%	-0.07	28.9%	50.7%	-0.24
Immunosuppressants (year up to index date)	5.6%	10.6%	-0.12	2.3%	2.9%	-0.03	5.7%	5.6%	0.00
Immunosuppressants (30 days up to index date)	3.9%	10.0%	-0.16	1.9%	2.6%	-0.03	3.5%	4.4%	-0.03
Immunosuppressants (on index date)	3.7%	10.0%	-0.17	1.7%	2.4%	-0.03	2.6%	4.0%	-0.05
Insulins and analogues (year up to index date)	17.8%	25.3%	-0.11	5.5%	3.3%	0.07	22.9%	27.1%	-0.06
Insulins and analogues (30 days up to index date)	10.9%	19.4%	-0.15	4.9%	3.3%	0.06	18.4%	20.3%	-0.03
Insulins and analogues (on index date)	9.9%	17.6%	-0.15	4.7%	3.1%	0.06	14.6%	19.5%	-0.08
Lipid modifying agents (year up to index date)	33.8%	31.2%	0.03	26.8%	16.3%	0.16	61.9%	55.0%	0.06
Lipid modifying agents (30 days up to index date)	20.8%	28.2%	-0.11	23.6%	14.9%	0.14	50.8%	48.5%	0.02
Lipid modifying agents (on index date)	18.7%	25.3%	-0.10	23.0%	14.4%	0.14	43.8%	47.3%	-0.04

CUIMC: Columbia University Irving Medical Center; HIRA: Health Insurance Review & Assessment; HM: HM Hospitales; PHD: Premier Healthcare Database; SIDIAP: The Information System for Research in Primary Care; UC HDC: University of Colorado Health Data Compass; VA OMOP: Department of Veterans Affairs. COPD: Chronic obstructive pulmonary disease; GERD: Gastroesophageal reflux disease. Exact proportions have not been reported where counts were less than 10.

Supplementary Methods.

Identifying a COVID-19 hospitalisation

The below tables summarise the concepts used to identify a COVID-19 hospitalisation. Alongside a hospitalisation visit, one of these codes needed to be observed. The full description of the logic used is provided at https://atlas.ohdsi.org/#/cohortdefinition/108. (Similarly, the full description of the logic used to identify hospitalisations with influenza is provided at https://atlas.ohdsi.org/#/cohortdefinition/108. (Similarly, the full description of the logic used to identify hospitalisations with influenza is provided at https://atlas.ohdsi.org/#/cohortdefinition/108.

COVID-19 condition codes

Id	Name	Vocabulary
3731106		
1	Disease caused by 2019-nCoV	SNOMED
3731028		
7	Myocarditis caused by 2019 novel coronavirus	SNOMED
3731028	Infection of upper respiratory tract caused by 2019 novel	
6	coronavirus	SNOMED
3731028		
5	Pneumonia caused by 2019 novel coronavirus	SNOMED
3731028		
4	Encephalopathy caused by 2019 novel coronavirus	SNOMED
3731028		
3	Gastroenteritis caused by 2019 novel coronavirus	SNOMED
3731025		
4	Otitis media caused by 2019 novel coronavirus	SNOMED
		OMOP
756081	Infection of lower respiratory tract due to COVID-19	Extension
		OMOP
756061	Asymptomatic COVID-19	Extension
		OMOP
756044	Acute respiratory distress syndrome (ARDS) due to COVID-19	Extension
		OMOP
756039	Respiratory infection due to COVID-19	Extension
		OMOP
756031	Bronchitis due to COVID-19	Extension
		ОМОР
756023	Acute bronchitis due to COVID-19	Extension

COVID-19 specific testing - Positive

Id		Name	Vocabulary
	37310282	2019 novel coronavirus detected	SNOMED

COVID-19 specific testing (note, these required a corresponding value as concept of: Detected, Positive, Positive, or Present)

Id	Name	Vocabu
		lary
402	Testing for SARS-CoV-2 in CDC laboratory	HCPCS
188		
05		
402	Testing for SARS-CoV-2 in non-CDC laboratory	HCPCS
188		
04		
373	Measurement of 2019 novel coronavirus antibody	SNOM
102		ED
58		
373	Measurement of 2019 novel coronavirus antigen	SNOM
102		ED
57		
373	Detection of 2019 novel coronavirus using polymerase chain reaction technique	SNOM
102		ED
55		
757	SARS-CoV-2 (COVID19) IgA+IgM [Presence] in Serum or Plasma by Immunoassay	LOINC
686		
757	SARS-CoV-2 (COVID19) neutralizing antibody [Presence] in Serum by pVNT	LOINC
680		
757	SARS-CoV-2 (COVID19) neutralizing antibody [Titer] in Serum by pVNT	LOINC
679		
757	SARS-CoV-2 (COVID19) N gene [Presence] in Nose by NAA with probe detection	LOINC
678		
757	SARS-CoV-2 (COVID19) RNA [Presence] in Nose by NAA with probe detection	LOINC
677		
756	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
085	using Nucleic acid amplification technique in Respiratory specimen	Extensi
		on
756	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
084	using Nucleic acid amplification technique in Unspecified specimen	Extensi
		on
756	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
065	in Unspecified specimen	Extensi
	-	on
756	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
055		Extensi
	-	on
756	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
029	in Respiratory specimen	Extensi
		on

723	SARS-CoV-2 (COVID19) Ab [Interpretation] in Serum or Plasma	LOINC
480		
723	SARS-CoV-2 (COVID19) IgG+IgM Ab [Presence] in Serum or Plasma by	LOINC
479	Immunoassay	
723	SARS-CoV-2 (COVID19) ORF1ab region [Presence] in Respiratory specimen by	LOINC
478	NAA with probe detection	
723	SARS-CoV-2 (COVID19) Ag [Presence] in Respiratory specimen by Rapid	LOINC
477	immunoassay	
723	SARS-CoV-2 (COVID19) RNA [Presence] in Nasopharynx by NAA with non-probe	LOINC
476	detection	
723	SARS-CoV-2 (COVID19) IgM Ab [Presence] in Serum or Plasma by Immunoassay	LOINC
475		
723	SARS-CoV-2 (COVID19) IgG Ab [Presence] in Serum or Plasma by Immunoassay	LOINC
474		
723	SARS-CoV-2 (COVID19) IgA Ab [Presence] in Serum or Plasma by Immunoassay	LOINC
473		
723	SARS-CoV-2 (COVID19) RdRp gene [Cycle Threshold #] in Respiratory specimen by	LOINC
471	NAA with probe detection	
723	SARS-CoV-2 (COVID19) RdRp gene [Cycle Threshold #] in Unspecified specimen	LOINC
470	by NAA with probe detection	
723	SARS-CoV-2 (COVID19) ORF1ab region [Cycle Threshold #] in Respiratory	LOINC
469	specimen by NAA with probe detection	
723	SARS-CoV-2 (COVID19) S gene [Cycle Threshold #] in Unspecified specimen by	LOINC
468	NAA with probe detection	
723	SARS-CoV-2 (COVID19) S gene [Cycle Threshold #] in Respiratory specimen by	LOINC
467	NAA with probe detection	
723	SARS-CoV-2 (COVID19) S gene [Presence] in Unspecified specimen by NAA with	LOINC
466	probe detection	
723	SARS-CoV-2 (COVID19) S gene [Presence] in Respiratory specimen by NAA with	LOINC
465	probe detection	
723	SARS-CoV-2 (COVID19) ORF1ab region [Presence] in Unspecified specimen by	LOINC
464	NAA with probe detection	
723	SARS-CoV-2 (COVID19) RNA [Presence] in Serum or Plasma by NAA with probe	LOINC
463	detection	
723	SARS-CoV-2 (COVID19) IgA Ab [Units/volume] in Serum or Plasma by	LOINC
459	Immunoassay	
715	SARS-CoV-2 (COVID19) N gene [Presence] in Nasopharynx by NAA with probe	LOINC
272	detection	
715	SARS-CoV-2 (COVID19) RNA [Log #/volume] (viral load) in Unspecified specimen	LOINC
262	by NAA with probe detection	
715	SARS-CoV-2 (COVID19) RNA [Presence] in Saliva (oral fluid) by Sequencing	LOINC
261	o and cover 2 (cover 20) martin connect in survey (or an indial by sequencing	
715	SARS-CoV-2 (COVID19) RNA [Presence] in Saliva (oral fluid) by NAA with probe	LOINC
260	detection	
706	SARS-CoV-2 (COVID19) IgG Ab [Presence] in Serum, Plasma or Blood by Rapid	LOINC
181	immunoassay	
706	SARS-CoV-2 (COVID19) IgM Ab [Presence] in Serum, Plasma or Blood by Rapid	LOINC
180	immunoassay	
	SARS-CoV-2 (COVID19) Ab panel - Serum or Plasma by Immunoassay	
706	AN PARE - SELUTI OF FIASHIA DY ITHITUTOASSAY	LOINC
179		

706	SARS-CoV-2 (COVID19) IgM Ab [Units/volume] in Serum or Plasma by	LOINC
178	Immunoassay	
706	SARS-CoV-2 (COVID19) IgG Ab [Units/volume] in Serum or Plasma by	LOINC
177	Immunoassay	
706	SARS-CoV-2 (COVID19) IgG and IgM panel - Serum, Plasma or Blood by Rapid	LOINC
176	immunoassay	
706	SARS-CoV-2 (COVID19) N gene [Presence] in Unspecified specimen by NAA with	LOINC
175	probe detection	
706	SARS-CoV-2 (COVID19) E gene [Presence] in Unspecified specimen by NAA with	LOINC
174	probe detection	
706	SARS-CoV-2 (COVID19) RdRp gene [Presence] in Unspecified specimen by NAA	LOINC
173	with probe detection	
706	SARS-CoV-2 (COVID19) RNA [Presence] in Unspecified specimen by NAA with	LOINC
170	probe detection	
706	SARS-CoV-2 (COVID19) RNA panel - Unspecified specimen by NAA with probe	LOINC
169	detection	
706	SARS-CoV-2 (COVID19) ORF1ab region [Cycle Threshold #] in Unspecified	LOINC
168	specimen by NAA with probe detection	
706	SARS-CoV-2 (COVID19) N gene [Cycle Threshold #] in Unspecified specimen by	LOINC
167	NAA with probe detection	
706	SARS-CoV-2 (COVID19) E gene [Cycle Threshold #] in Unspecified specimen by	LOINC
166	NAA with probe detection	
706	SARS-CoV-2 (COVID19) RNA [Presence] in Respiratory specimen by NAA with	LOINC
163	probe detection	
706	SARS-CoV-2 (COVID19) N gene [Presence] in Respiratory specimen by NAA with	LOINC
161	probe detection	
706	SARS-CoV-2 (COVID19) RdRp gene [Presence] in Respiratory specimen by NAA	LOINC
160	with probe detection	
706	SARS-CoV-2 (COVID19) RNA panel - Respiratory specimen by NAA with probe	LOINC
158	detection	
706	SARS-CoV-2 (COVID19) N gene [Cycle Threshold #] in Unspecified specimen by	LOINC
157	Nucleic acid amplification using CDC primer-probe set N1	
706	SARS-CoV-2 (COVID19) N gene [Presence] in Unspecified specimen by Nucleic	LOINC
156	acid amplification using CDC primer-probe set N1	
706	SARS-CoV-2 (COVID19) N gene [Cycle Threshold #] in Unspecified specimen by	LOINC
155	Nucleic acid amplification using CDC primer-probe set N2	
706	SARS-CoV-2 (COVID19) N gene [Presence] in Unspecified specimen by Nucleic	LOINC
154	acid amplification using CDC primer-probe set N2	
705	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
107	in Sample from nose	Extensi
		on
705	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
106	using Nucleic acid amplification technique in Sample from nose	Extensi
		on
705	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
001	using Nucleic acid amplification technique	Extensi
		on
705	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
000	using Nucleic acid amplification technique in Blood	Extensi
		on

704	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
993	using Sequencing	Extensi
555		on
704	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
992	using Culture method	Extensi
352	using culture method	on
704	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
991	in Blood	Extensi
991		
700	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory	on CPT4
360	syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]),	CP14
500	amplified probe technique	
F 96		
586	SARS-CoV-2 (COVID19) RNA [Cycle Threshold #] in Unspecified specimen by NAA	LOINC
529	with probe detection	
586	SARS-CoV-2 (COVID19) RNA [Cycle Threshold #] in Respiratory specimen by NAA	LOINC
528	with probe detection	
586	SARS-CoV-2 (COVID19) IgG Ab [Presence] in DBS by Immunoassay	LOINC
527		
586	SARS-CoV-2 (COVID19) RNA [Presence] in Nasopharynx by NAA with probe	LOINC
526	detection	
586	SARS-CoV-2 (COVID19) N gene [Presence] in Respiratory specimen by Nucleic	LOINC
525	acid amplification using CDC primer-probe set N2	
586	SARS-CoV-2 (COVID19) N gene [Presence] in Respiratory specimen by Nucleic	LOINC
524	acid amplification using CDC primer-probe set N1	
586	SARS-CoV-2 (COVID19) E gene [Presence] in Respiratory specimen by NAA with	LOINC
523	probe detection	
586	SARS-CoV-2 (COVID19) Ab [Units/volume] in Serum or Plasma by Immunoassay	LOINC
522		
586	SARS-CoV-2 (COVID19) IgA Ab [Presence] in Serum, Plasma or Blood by Rapid	LOINC
521	immunoassay	
586	SARS-CoV-2 (COVID19) N gene [Presence] in Serum or Plasma by NAA with probe	LOINC
520	detection	
586	SARS-CoV-2 (COVID19) S gene [Presence] in Serum or Plasma by NAA with probe	LOINC
519	detection	
586	SARS-CoV-2 (COVID19) E gene [Presence] in Serum or Plasma by NAA with probe	LOINC
518	detection	
586	SARS-CoV-2 (COVID19) whole genome [Nucleotide sequence] in Isolate by	LOINC
517	Sequencing	
586	SARS-CoV-2 (COVID19) [Presence] in Unspecified specimen by Organism specific	LOINC
516	culture	
586	SARS-CoV-2 (COVID19) Ab [Presence] in Serum or Plasma by Immunoassay	LOINC
515		
586	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
310	Genetic material using Molecular method	Extensi
		on
586	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
309	in Specified specimen	Extensi
		on
586	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
308	using Nucleic acid amplification technique in Saliva	Extensi
		on

ſ	586	Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	OMOP
	307	in Saliva	Extensi
			on

COVID-19 source codes

		Vocabul
Id	Name	ary
4575609		
3	Emergency use of U07.1 COVID-19, virus identified	ICD10
4560047		ICD10C
1*	Other coronavirus as the cause of diseases classified elsewhere	Μ
4250111	Emergency use of U07.1 Disease caused by severe acute respiratory	
5	syndrome coronavirus 2	KCD7
710160	Emergency use of U07.1 COVID-19, virus identified	ICD10CN
710159	COVID-19, excluding pneumonia	ICD10CN
710158	COVID-19	ICD10CN
710156	COVID-19 pneumonia	ICD10CN
710155	COVID-19 pneumonia	ICD10CN
586415*	Provisional assignment of new diseases or emergency use	KCD7
586414*	Novel coronavirus infection	KCD7

*Omitted for CUIMC to avoid including non-COVID-19 patients.